The Efficacy Results and Safety Profile of Imipenem/Cilastatin from the Clinical Research Trials

Publisher Website
Google Scholar
Abstract
Imipenem/cilastatin is highly effective for infections in many body sites against a broad range of gram‐positive and gram‐negative aerobic and anaerobic bacteria. During therapy, development of resistance is uncommon except in the case of Pseudomonas aeruginosa in which the incidence appears similar to that for other beta‐lactam antibiotics. There appears to be a very low probability of cross‐resistance. The clinical and laboratory adverse reactions are similar in type to those for other beta‐lactam antibiotics. The frequency of colonization and superinfection during treatment with imipenem/cilastatin has been comparable to other antibiotics in comparative trials and to literature reports for other antibiotics for noncomparative trials.

This publication has 25 references indexed in Scilit: